Skip to main content

Table 4 Chemotherapy or immunosuppressive treatment in PML patients without hematopoietic stem cell transplantation

From: Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan

Patient

Age

Sex

Underlying disease

Chemotherapeutic or immunosuppressive agents

9

78

M

Non-Hodgkin's lymphoma

CPA, THP, VDS, PSL, R

10

66

M

Non-Hodgkin's lymphoma

CPA, DXR, VCR, PSL, R

11

72

F

Non-Hodgkin's lymphoma

CPA, DXR, VCR, PSL, THP, R

12

64

F

Non-Hodgkin's lymphoma

CPA, DXR, VCR, PSL, ETP

13

77

M

Adult T-cell leukemia

CPA, DXR, VCR, PSL

14

64

M

Multiple myeloma

DEX, DXR, VCR, Bzb

15

67

M

Chronic lymphocytic leukemia

CPA

16

71

M

Primary macroglobulinemia

R

17

62

M

Non-Hodgkin's lymphoma

NA

18

22

M

Primary immunodeficiency syndrome

NA

19

24

M

Primary immunodeficiency syndrome

NA

  1. M, male; F, female; CPA, cyclophosphamide; THP, pirarubicin; VDS, vindesine; PSL, prednisolone; R, rituximab; DXR, doxorubicin; VCR, vincristine; ETP, etoposide; DEX, dexamethasone; Bzb, bortezomib; NA, not administered.